anu a str	200 (4-1-5-1) P. C. DEDADTATENT	OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
			13203
T	RANSMITTAL LETTER	TO THE UNITED STATES	
	DESIGNATED/ELECTE	D OFFICE (DO/EO/US)	U.S APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.5)
	CONCERNING A FILIN	G UNDER 35 U.S.C. 371	09/424629
NTERNA	TIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
	PCT/AU98/00396	28 May 1998 (28.05.98)	28 May 1997 (28.05.97) 30 May 1997 (3
	INVENTION		or MASS SEPARATION AND BASE (19.
	IC ACID DIAGNOSTICS BA FIC CLEAVAGE	SED ON MASS SPECINOMETRI	OR MASS SEI ARATION AND BASE (15.
PPLICA: Simon F	NT(S) FOR DO/EO/US Foote Gavin Reid		
	Simpson Colleen	lso	
	-	ites Designated/Flected Office (DO/FO/US) the following items and other information
l. 🗵		tems concerning a filing under 35 U.S.C. 3	
2.		UENT submission of items concerning a fi	
3.	examination until the expiration	in national examination procedures (35 U.S. of the applicable time limit set in 35 U.S.C.	2. 371(b) and PCT Articles 22 and 39(1).
4. 🗵	A proper Demand for Internation	nal Preliminary Examination was made by t	he 19th month from the earliest claimed priority date.
5.		ication as filed (35 U.S.C. 371 (c) (2))	
		(required only if not transmitted by the In-	ternational Bureau).
		y the International Bureau.	
	c 🗆 is not required, as the	application was filed in the United States R	eceiving Office (RO/US).
6. □	A translation of the Internationa	Application into English (35 U.S.C. 371(c)(2)).
7.	- ·		
8 🗵		e International Application under PCT Artic	
		th (required only if not transmitted by the Ir	nternational Bureau).
		by the International Bureau.	
		owever, the time limit for making such ame	ndments has NOT expired.
	d ⊠ have not been made an		S.C. 271/->/2))
9. [s to the claims under PCT Article 19 (35 U.	S.C 371(c)(3))
10. [_	An oath or declaration of the in	• • •	0)
11. ⊠ 12. □	A copy of the International Pres	minary Examination Report (PCT/IPEA/40 he International Preliminary Examination F	9) Renort under PCT Article 36
14. [(35 U S C 371 (c)(5))	the international Fernimary Examination 1	coport interior of the detection
Item	is 13 to 18 below concern docume	nt(s) or information included:	
13.		ement under 37 CFR 1 97 and 1.98	
14.			nce with 37 CFR 3 28 and 3 31 is included
15. 🗵			
	A SECOND or SUBSEQUEN	f preliminary amendment	
16. I	A substitute specification		
17. I	A change of power of attorney a	nd/or address letter	
18. ×	Certificate of Mailing by Expre	ss Mail	
19.	Cother items or information		
	Courtesy copy of internationa		
	Thirteen (13) sheets of drawing	ngs	

514 Rec'd PCT/PTO 2 4 NOV 1999

U.S. AP	LICATION	99F XN4W2SEE 6289		ATTORNEY'S DOCKET NUMBER						
·		17/464061	PCT/AU98/	/00396		13203				
20.	The foll	owing fees are submitted:.			CA	LCULATIONS	PTO USE ONLY			
		L FEE (37 CFR 1.492 (a) (1)								
	-	rt has been prepared by the EPC		\$840	.00					
		preliminary examination fee pa		\$670	.00					
	but internation	onal preliminary examination feonal search fee paid to USPTO	$(37 \text{ CFR } 1.445(a)(2)) \dots$	1.482) . \$760	.00					
	international	national preliminary examination search fee (37 CFR 1.445(a)(2) paid to USPTO		.00					
	International and all claim	preliminary examination fee pass satisfied provisions of PCT A	nid to USPTO (37 CFR 1.48 rticle 33(2)-(4)	82) . \$96 .	00					
		ENTER APPROPR	IATE BASIC FEE	AMOUNT =		\$970.00				
Surcha nonths	rge of \$130.0 s from the ear	0 for furnishing the oath or decliest claimed priority date (37	CFR 1.492 (e)).	□ 20 🗵 30)	\$130.00				
CL	AIMS	NUMBER FILED	NUMBER EXTRA	RATE						
Γotal c	laims	* 32 - 20 =	12	x \$18.0	0	\$216.00				
ndepe	ndent claims	* 5 - 3=	2	x \$78.0	0	\$156.00				
Multip	ple Depender	t Claims (check if applicable)				\$0.00				
		TOTAL O	F ABOVE CALCUI	LATIONS	=	\$1,472.00				
Reduct nust a	tion of 1/2 for lso be filed (filing by small entity, if application of the filling by small entity, if application of the filling by the fil	cable. Verified Small Entity check if applicable).	y Statement		\$0.00				
			S	UBTOTAL	=	\$1,472.00				
roces	sing fee of \$1 s from the ear	30.00 for furnishing the Englishiest claimed priority date (37)	h translation later than CFR 1.492 (f)).	□ 20 □ 3	0 +	\$0.00				
<u>-</u>			TOTAL NATIO	NAL FEE	=	\$1,472.00				
ee for	r recording the	e enclosed assignment (37 CFR appropriate cover sheet (37 CF)	1.21(h)). The assignment	must be		\$0.00				
			TOTAL FEES EN		=	\$1,472.00				
*C]	laim calc	ulation based on cl	aims as amended	by Prelim	inary	nount to be:	\$			
A m	endment	being filed concur	rently herewith	2		charged	\$			
×	A check in	the amount of \$1,472.00	to cover the above fees	is enclosed						
	Di		in the amo	wnt of		to cover the abov	e fees			
Ц		rge my Deposit Account No.		out of		to cover the abov	C ICCs.			
	A duplicat	te copy of this sheet is enclosed								
X		uissioner is hereby authorized to Account No 19-1013/SSMP			credit any	overpayment				
NOTI 1.137(E: Where an (a) or (b)) m	appropriate time limit under ust be filed and granted to res	37 CFR 1.494 or 1.495 hatore the application to per	as not been met, nding status.	a petitio	to revive (37 C)	fr A			
SEND	ALL CORR	ESPONDENCE TO			$\mathcal{A}l$	a <i>M</i> M9/M	7			
Leon	old Presser			SIGNAŤ		10000				
SCU	LLY, SCOT	T, MURPHY & PRESSER			/ '	<i>"</i>				
	Garden City			Leopolo	d Presser	•				
	den City, NY) 742-4343	11530		NAME						
(210)	, /7 4-737 3			19,827						
					RATION	NUMBER				
					ber 24, 1	yyy 				
				DATE						

Colleen ELSO Richard SIMPSON & Gavin REID

Surial or latent No.: Kichard Stir von a Gavin Kuto hocket No:	
riled or leaved: Nucleic acid diagnostics based on mass spectrometry or mass	
separation and base specific cleavage" ventred statement (declaration) claded shall entity status (37 CFR 1.9(f) and 1.27(d)) - NOPROFIT ORGANIZATION I hereby declare that I am an official empowered to act on behalf of the nomprofit	
VERLETED STATEMENT (DECLARATION) CLADENC SHALL ENTITY STATUS	
(37 CTR 1.9(f) and 1.27(d)) - NONPROFIT ORGANIZATION	
I hereby declare that I am an official empowered to act on behalf of the nonprofit	
organization identified below: THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESE	ARC
NAME OF ORGANIZATION Royal Parade. Parkville. Victoria. 3052,	
Australia Royal Filling Farker File Victoria South	
TYPE OF ORCHVIERTION	
1 UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION	
[] TAX EXPERT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c) (31)	
K) NONPROPITE SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA	
(NAME OF STATUTE	
[] WOULD QUALIFY AS TAX EXPLYT UNDER INTERNAL REVENUE SERVICE CODE [26 USC 501(a)	
and 501(c)(3)) If located in the united states of america (()) Would qualify as nonprofit scientific or educational under statute of state of	
THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA	
(NAME OF STATE)	

I hereby declare that the nomprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced faces	
under section 41(a) and (b) of Title 35, United States Code with regard to the invention	
entitled Same as above by inventor (s) Same as above described in	
[] the specification filed herewith	
] application serial no, filed	
National Phase Entry of International Patent Application	No.
I hereby declare that rights under contract or law have been conveyed to and remain with	
the nonprofit organization with regard to the above identified invention.	
If the rights held by the nonprofit organization are not exclusive, each individual,	
concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as a	
small business concern under 37 CFR 1.91d) or by any concern which would not qualify as a	
would business concern under 37 CTR 1.9(d) or a nonprofit organization under 37 CTR 1.9(e). *NOTE: Separate verified statements are required from each named person, concern	
of organization having rights to the invention everring to their status as small entities.	
(37 CPR 1.27)	
NATE NOODE	
ADDRESS DIDIVIOUAL SMALL BUSINESS CLASSIN NUMBER OF THE PROPERTY OF THE	
NAVE.	
AD(402)	
INDIVIOUAL	
I a lumbered the duty to file, in this application or parent, notification of any change	
in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the	
thre on which status as a small entity is no longer appropriate. (37 CFR 1,28(b))	
I hereby declare that all statements made herein of my own knowledge are true and that all	
Statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made	
are punishable by line or imprisorment, or both, under secrious 1001 of Title 18 of the	
United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified	
Statement is directed.	
NAME OF PERSON SIGNEDS: Dr Margaret Brumby - General Manager	
TITLE IN ORGANIZATION The Walter and Eliza Hall Institute of Medical Research	
Royal Parade, Parkville, Victoria, 3052.	
ignature: Die x 17.02.2000	

09/424629 514 Rec'd PCT/PTO 2 4 NOV 1999

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Simon Foote et al. Examiner:

Serial No.: to be assigned Art Unit: unassigned

Filed: concurrently herewith Docket: 13203

For: NUCLEIC ACID DIAGNOSTICS Dated: November 24, 1999

BASED ON MASS SPECTROMETRY OR MASS SEPARATION AND BASE SPECIFIC CLEAVAGE

Assistant Commissioner for Patents Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

In connection with the filing of the above-described application, kindly enter the following preliminary amendments.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number: EM341609046US Date of Deposit: November 24, 1999

I hereby certify that this Preliminary Amendment is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 2023

Dated: November 24, 1999

Mishelle Spina

AMENDMENTS

IN THE CLAIMS:

Please amend claims 3, 6, 8, 12, 15, 17, 26, 29 and 31 as follows:

Claim 3, line 1, please delete "or 2";

Claim 6, line 1, please amend "any one of claims 1 to 5" to read --claim 1--;

Claim 8, line 1, please amend "any one of claims 1 to 7" to read --claim 1--;

Claim 12, line 1, please delete "or 10";

Claim 15, line 1, please amend "any one of claims 9 to 13" to read --claim 9--;

Claim 17, line 1, please amend "any one of claims 10 to 16" to read --claim 10--;

Claim 26, line 1, please delete "or 25";

Claim 29, line 1, please amend "any one of claims 24 to 28" to read --claim 24--; and

Claim 31, line 1, please amend "any one of claims 24 to 30" to read --claim 24--.

REMARKS

As originally prepared, Claims 6-9, 15-18 and 29-32 did not comply with the multiple dependent claim style

specified by U.S. law. The amendments submitted herewith have been made to eliminate all multiple dependencies. It is respectfully submitted that no new matter has been introduced by so doing.

It is respectfully requested that the above amendments be entered before an action on the merits is issued.

Respect fully supmitted,

Leopold Presser

Registration Nb. 19,827

SCULLY, SCOTT, MURPHY & PRESSER 400 Garden City Plaza Garden City, New York 11530 (516) 742-4343

LP/vjs

- 1 -

NUCLEIC ACID DIAGNOSTICS BASED ON MASS SPECTROMETRY OR MASS SEPARATION AND BASE SPECIFIC CLEAVAGE

FIELD OF THE INVENTION

5 The present invention relates generally to a method for detecting a mutation in a nucleic acid molecule. The method of the present invention does not require prior knowledge of a reference or wild-type nucleotide sequence nor does it require a gel electrophoresis step. The method of the present invention is particularly useful in identifying mutations and polymorphisms in genomic DNA and more particularly in the human genome and to determine and/or confirm the 10 nucleotide sequence of target nucleic acid molecules. The method of the present invention may also be automated.

BACKGROUND OF THE INVENTION

15 Bibliographic details of the publications referred to by author in this specification are collected at the end of the description.

The increasing sophistication of recombinant DNA technology is greatly facilitating research and development in a range of biotechnological fields. A particularly important area is the generation 20 of nucleotide mutants and the screening for and identification of such mutants. This in turn has implications, for example, in understanding the genetic basis behind certain disease conditions which is becoming of increasing relevance as the human genome is progressively sequenced.

An efficient and accurate method of mutation detection is crucial in implicating disease candidate 25 genes and in the screening programs which follow identification of disease causing mutations. Many human inherited and sporadic disorders are caused by small mutations including base substitutions, additions and deletions. Among these disorders are the Mendelian single gene disorders, sporadic somatic mutations causing cancers and complex genetic traits. Whilst some diseases are caused by a limited and well characterised set of mutations, most genetic diseases 30 are caused by one or more of a large range of mutations occurring anywhere within the gene. It is important, therefore, that a mutation detection protocol be able to scan a region of DNA, identify any change and describe the resulting nucleotide differences from wild-type. With the increasing use of population molecular genetics and as clinicians begin to use mutation analysis as a clinical tool, there is a need to develop mutation detection protocols which can be automated, are less dependant on user expertise and are more accurate and reliable.

5

Current mutation detection protocols require either a gel based detection system or sequence specific primers. Gel based detection methods include direct sequencing of amplified DNA fragments and various techniques involving either cleavage of mismatched bases in heteroduplexes or mobility differences of single or partially denatured DNA strands.

10

Detection of mutations by DNA sequencing can provide good results in relation to accuracy and information about the position and nature of the mutation (Hattori *et al*, 1993), however, although advances have been made in this area, the technique is not fully automated and is labour intensive. Most mutations occur as heterozygotes and there are technical difficulties with the ability of currently available computer software to identify two different nucleotide bases at a mutated residue.

Many mutation detection techniques exploit differential electrophoretic mobilities of DNA fragments with sequence differences. Single strand conformation polymorphism (SSCP) exploits the fact that the secondary structure of a single strand of DNA is sequence based and, therefore, strands with even just one base difference will migrate at a different rate (Orita et al, 1989). This technique is again gel based and can lack sensitivity. Furthermore, the method cannot be readily automated and requires a large amount of labour due to the necessary gel step which in most cases must be optimised to the specific sample being analysed. They also do not give any information about the position or nature of the change and do not routinely identify all mutations.

Mutation detection based on the identification of base pair mismatches in heteroduplex DNA strands is another method of identifying point changes. There are a number of techniques available that cleave DNA at mismatched base pairs in heteroduplex DNA. Mismatch cleavage protocols include chemical and enzymatic mismatch cleavage. The techniques are also gel based. The chemical cleavage method uses osmium tetroxide to cleave at the mismatched base (Cotton

- 3 -

et al, 1988) followed by separation of cleaved products on denaturing gels. A major disadvantage of the chemical cleavage protocol is the use of extremely toxic chemicals.

Other methods for detection of known mutations include minisequencing allele specific polymerase chain reaction (PCR), oligonucleotide probe arrays (Lipshutz *et al*, 1995) which requires knowledge of the sequence of wild-type and mutant. Although this technique is suitable for non-gel based detection methods, it is only useful for know mutations. Furthermore, the large number of oligonucleotides required to cover all known mutations in many genes makes this approach prohibitively expensive and labour intensive.

10

With the development of the matrix assisted laser desorption ionisation - time of flight mass spectrometer (MALDI-TOF MS), the ability to accurately determine the mass of biomolecules of a limited size has been achieved. Although detection of DNA fragments of up to 622 base pairs in length has been reported, large fragments cannot be accurately sized and a mass accuracy of ±3bp is quoted (Liu et al, 1995). This level of accuracy is clearly insufficient for the detection and characterisation of base substitutions.

There is a need, therefore, to develop an effective and accurate means of detecting mutations in nucleic acid molecules. Preferably, the mutation detection system would be automatable.

20

In work leading up to the present invention the inventors developed a mutation detection system which exploits the accuracy of mass determination of MALDI-TOF MS and which is applicable for large DNA fragments. The method of the present invention do not require gel electrophoresis nor is prior knowledge of the nucleotide sequence necessary. The method of the present invention is also capable of being automated.

SUMMARY OF THE INVENTION

Sequence Identity Numbers (SEQ ID NOs.) for the nucleotide and amino acid sequences referred to in the specification are defined following the bibliography.

5

Ĭ

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

10

One aspect of the present invention contemplates a method of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising subjecting the test nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.

20

Another aspect of the present invention provides a method of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising amplifying said test nucleic acid molecule by polymerase chain reaction (PCR), subjecting the test amplified nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.

X

WO 98/54571 PCT/AU98/00396

- 5 -

Yet another aspect of the present invention is directed to a method of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising amplifying said test nucleic acid molecule by PCR, subjecting the test amplified nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments of from about 2 to about 1000 bases, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.

Still yet another aspect of the present invention relates to a method of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising amplifying said test nucleic acid molecule and incorporating uracil residues, subjecting the test amplified nucleic acid molecule to uracil specific cleavage mediated by a uracil-N-glycosylase to generate oligonucleotide fragments of from about 2 to about 1000 bases, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.

Another aspect of the present invention contemplates a computer programme capable of controlling a method of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising subjecting the test nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an

Ċ

15

altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.

Yet another aspect of the present invention is directed to an apparatus capable of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said apparatus comprising means of subjecting the test nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.

Still another aspect of the present invention provides a method of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising subjecting the test nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure and subjecting said separated fragments to further separation means, such as post source decay (PSD) or other similar technique, to separate fragmentation products to generate a spectrum dependent on nucleotide sequence and then identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative

25 of a difference of one or more nucleotides in said tested nucleic acid molecule.

¥

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a graphical representation showing mass spectrogram of cleavage products of two oligonucleotides, 1 and 2, which differ at two nucleotides, one produces a fragment with a different nucleotide composition and the other introducing a new cleavage site. The two line thicknesses represent the overlaid tracings of the two different oligonucleotides. 1636.3 represents a thick line peak and 3190.9 represents a thin line peak. 1811.1 is a thin line peak and 1828.2 is a thick line peak. Kratos Kompact MALDI 4v51.2; % int. 100% = 24mV (thin); 81mV (thick).

10

Figure 2 is a graphical representation showing mass spectrogram of reacted, separated products of normal TUB which represents a homozygote. Mode: linear; Accelerating Voltage: 20,000; Grid Voltage: 92.000%; Guide Wire Voltage 0-100%; Delay 125ON; Laser:1800; Scans Averaged: 128; Pressure: 9.94e-07; Low Mass Gate: 900.0; Negative Ions: ON.

15

Figure 3 is graphical representation showing mass spectrogram of reacted, separated products of both TUB-M and TUB which represents a heterozygote. Mode: linear; Accelerating Voltage: 20,000; Grid Voltage: 92.000%; Guide Wire Voltage 0-100%; Delay 125ON; Laser: 1800; Scans Averaged: 128; Pressure: 1.89e-06; Low Mass Gate 900.0; Negative Ions: ON.

20

Figure 4 is a representation of the nucleotide sequence of IL-12 untranslated region PCR product used in Example 13. Primers are shown in bold. Expected cleavage products >2bp are underlined. The polymorphism is at position 97 and is indicated by asterisk. The polymorphism is a C to T change which results in a change of the cleavage products at that position from CGA to AGA in the forward strand and CAAGC to CAA in the reverse stand. The presence of C at position 97 results in a TaqI site and this allele is called "+", the other allele is respectively "-".

Figure 5A is a photographic representation of a TaqI restriction digest of IL-12 PCR products from +/- individuals (lanes 1, 4 and 5), a +/+ individual (lane 3) and a -/- individual (lane 2). The 30 124 bp fragment is cleaved by TaqI (where possible) to produce 97 and 27 bp fragments.

ĸ

-8-

Figure 5B is a graphical representation showing linear MALDI-TOF spectra of cleavage products. The spectra on the left show a mass range of 1000 to 3500 and those on the right are the same spectra but show in detail the mass range from 1000 to 1700. Spectra *i* a and b are from a -/- individual, spectra *ii* a and b are from a +/+ individual and spectra *iii* a and b are from 5 a +/- individual. Observed masses are indicated above peaks. Arrows show the peaks that change between the two alleles.

Figure 6 is a graphical representation of the mass spectrum analysed using post source decay (PSD) on a MALDI-TOF instrument. Spectrum A is a 6mer of sequence CATCCT [SEQ ID 10 NO:16] and spectrum B a 6mer of sequence CACCTT [SEQ ID NO:17]. Both have parent ion mass of 1727.2Da. Observed masses are shown above the peaks. PSD fragments are shown at an intensity magnification of five.

خ

- 15 Accordingly, one aspect of the present invention contemplates a method of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising subjecting the test nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure to produce a 20 fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.
- 25 Conveniently, screening is carried out by comparing the cleavage product masses of the reference or wild-type nucleic acid to those of the test sample. Mass changes corresponding to base changes are readily observed.

Accurate mass determination of these small fragments is possible allowing unambiguous assignation of base composition of each oligonucleotide. This knowledge allows deduction of the nature of the mutation and, after specific cleavage at different bases and integration of the

Ľ

data, the position of the mutation.

The method of the present invention is applicable to any nucleic acid molecule such as but not limited to DNA, genomic DNA, cDNA, plasmid DNA, satalite DNA, mRNA and other RNA molecules as well as DNA:DNA, DNA:RNA and RNA:RNA hybrids. The present invention is particularly applicable to nucleic acid molecules amplified by, for example, polymerase chain reaction (PCR).

According to this aspect of the present invention, there is provided a method of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising amplifying said test nucleic acid molecule by polymerase chain reaction (PCR), subjecting the test amplified nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.

20

A particularly preferred requirement is that the source of nucleic acid is cleavable to oligonucleotide fragments of from 2 bases to 1000 bases, preferably of from 3 bases to 500 bases, more preferably of from 4 bases to 100 bases and even more preferably of from 4 bases to 50 bases. Oligonucleotide fragments of form 4 bases to 40 bases are of particular usefulness 25 in practising the present invention.

Accordingly, the present invention is directed to a method of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising amplifying said test nucleic acid molecule by PCR, subjecting the test amplified nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments of from about 2 to about 1000 bases, separating the resulting oligonucleotide

٤

fragments based on mass by MALDI-TOF MS and/or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.

The nucleic acid may be cleaved by a range of chemical molecules including enzymes. Enzymes are particularly preferred due to their specificity. One useful enzyme is uracil-N-glycosylase which cleaves DNA at uracil residues incorporated, for example, during a PCR. However, a range of enzymes may be employed.

According to this embodiment, the present invention relates to a method of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising amplifying said test nucleic acid molecule and incorporating uracil residues, subjecting the test amplified nucleic acid molecule to uracil specific cleavage mediated by a uracil-N-glycosylase to generate oligonucleotide fragments of from about 2 to about 1000 bases, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.

The method of the present invention is predicated in part on the fact that any oligonucleotide fragment differing in nucleotide composition between mutant and wild-type (or reference) sequences will be detected. The method has advantages over previously employed techniques and such advantages include the absence of a gel electrophoresis step thereby reducing time, expertise and need for separation equipment and the lack of dependance on toxic chemicals, such as osmium tetroxide. Whilst the present invention extends to the use of such chemicals in base specific cleavage reactions, it is preferred to use an enzymatic reaction to cleavage the target nucleic acid molecule.

ž

The method of the present invention is particularly useful in detecting previously unknown mutations. This is important as a screening mechanism for inherited diseases and cancers such as during pre-natal diagnosis, diagnosis of a suspected disease or screening for carriers of disease alleles. It also has applications in polymorphism analysis of populations and in studies of evolution, drug resistance, virulence or attenuation of disease agents such as bacteria, viruses or protozoa.

The method may be carried out simultaneously or sequentially with an analysis of a reference to wild-type nucleic acid molecule. Both the test and reference nucleic acid molecules can then be compared. Alternatively, the wild-type nucleic acid molecule may already have been analysed. Conveniently, this information may be stored electronically and upon completion of the analysis of the test nucleic acid molecule, both the test and reference sequences may then be compared manually, electronically or by a computer assisted means.

15 The method of the present invention may also be used to determine the nucleotide sequence of a nucleic acid molecule.

The nucleotide sequence may be completely determined or a partial sequence obtained for example, for selected nucleotides. The method of the present invention, therefore, permits the rapid determination of a nucleotide sequence which will be invaluable, for example, in the efficient analysis of mutations.

The method of the present invention may be semi or fully automated and the present invention extends to apparatuses for automating the mutation detection assay. The apparatus may also be electronically controlled by a computer programme to facilitate the automation and/or analysis process.

Accordingly, another aspect of the present invention contemplates a computer programme capable of controlling a method of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising subjecting the test nucleic acid molecule to base specific cleavage to generate oligonucleotide

fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.

Yet another aspect of the present invention is directed to an apparatus capable of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a 10 reference nucleic acid molecule, said apparatus comprising means of subjecting the test nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak 15 relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.

In a particularly preferred embodiment, the method of apparatus of the present invention also employs a further fragment separation means such as but not limited to post source decay (PSD). PSD, for example, uses the dissociation of highly energised ions during their flight to the detector creating a second dimension. The ions are directed into an electric field of opposite polarity and are reflected. Smaller ions are reflected earlier and reach the detector first. As the spectrum from the decay is dependent on the nucleotide sequence of an oligonucleotide rather than the nucleotide composition, this avoids missing mutations in an oligonucleotide having the same nucleotide composition as a reference oligonucleotide. Although PSD is one convenient fragment separation means, the present invention extends to other similar techniques to separate fragmentation products. Generally these techniques are based on mass although may also be based on electrophoretic mobility, base size, base charge, base paring or other suitable criteria.

30

Accordingly, another aspect of the present invention provides a method of detecting a difference

- 14 -

of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising subjecting the test nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure and subjecting said separated fragments to further separation means to generate a spectrum dependent on nucleotide sequence and then identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.

10 The MALDI-TOF MS analysis and further separation means may be done sequentially or simultaneously.

Preferably, the further separation means includes or comprises PSD or other similar techniques to separate fragmentation products.

15

The present invention is particularly useful in identifying and/or locating mutants in heterozygotes. Mutations are detectable on both strains or on one strand only.

Yet another aspect of the present invention provides a method for identifying and/or locating a mutation in one or more bases in a target nucleic acid molecule, subjecting the test nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.

Preferably, the separated fragments are subjected to further separation means such as but not 30 limited to PSD.

The present invention is further described by the following non-limiting Examples.

EXAMPLE 1 OLIGONUCLEOTIDES

Two test 22mers oligonucleotides with two bases different were used in this study

5

CCT CAT UTT TTU TTG TAA GAG G [SEQ ID NO:1]
CCT CGT UTT TTU TTG TUA GAG G [SEQ ID NO:2]

The different bases are shown in bold.

10

For the detection of point mutations (see Example 7), the following oligonucleotides are used:

TUB:

GGT GAC CTG AAC CAC CTC GTG CGT CCA GCC GTT CGT GGC TGT CCA GTC CGC

15 GAAC TCT GAC CTG CGC AAG [SEQ ID NO:3]

TUB-M:

GGT GAC CTG AAC CAC CTC GTG CGT CCA GCC GTT CGA GGC TGT CGA GTC CGCGAA CTC TGA CCT GCG CAA G [SEQ ID NO:4]

TUB-F:

20 GGT GAC CTG AAC CAC CTC GT [SEQ ID NO:5]

TUB-R:

CTT GCG CAG GTC AGA GTT [SEQ ID NO:6]

TUB and TUB-M are used as template DNA and differ at three residues, bolded above, which comprise two point mutations and one insertion (bracketed and bolded). TUB-F and TUB-R are the "reverse" and "forward" primers used to amplify either TUB or TUB-M in a polymerase chain reaction.

EXAMPLE 2 CLEAVAGE REACTION

The cleavage reactions were carried out using 100 pmol of oligonucleotide, 0.5 units uracil -N-5 glycoslyase (Perkin - Elmer) 1xPCR buffer (50mM KCl, 10mM Tris-HCl pH 8.3) (Perkin-Elmer) in a 250µl reaction. The reaction mixture was incubated at 50°C for 20 minutes to allow cleavage of the N-glycosidic bond at uracil. It was then heated for 15 minutes to 105°C to allow degradation of the phosphate bonds at the basic sites. The mixture was then purified using anion exchange resin to remove buffer salts and other impurities.

10

EXAMPLE 3 SAMPLE PURIFICATION

Qiagen Anion Exchange Resin was equilibrated in 5mM NH₄HCO₃ (Sigma) pH 8.4 (sodium free). 40μl of the slurry was added to the reaction mixture and the DNA was allowed to bind at room temperature for 5 minutes with gentle shaking. The beads were spun down in a bench centrifuge and the supernatant discarded. The beads were then washed with 3x100μl volumes of 5mM NH₄HCO₃ pH 8.4 (sodium free) with incubation and centrifugation between each wash. The supernatant was discarded each time. The DNA fragments were then eluted using two 40μl volumes of 0.5M NH₄HCO₃ pH 8.0 (sodium free), with incubation and centrifugation as before but with the supernatant being kept. The supernatant was then evaporated to dryness on a Savant Speedivac and resuspended twice in 20μl distilled water and evaporated to dryness to remove any residual NH₄HCO₃. The final product was resuspended in 5μl distilled water. The final concentration being approximately 20pmol/μl.

25

EXAMPLE 4 THE POLYMERASE CHAIN REACTIONS AND DNA URACIL GLYCOSYLASE REACTION

30 20 ul reactions were set up containing 2.5mM MgCl₂, 2.5 mM dATP, dCTP, dGTP, 5 mM dUTP, 0.5U Taq Gold (Perkin Elmer), 1.5 mM each TUB-F and TUB-R oligonucleotides and

2.4 fg or either TUB or TUB-M or a mix of both. PCR assays were incubated at 95°C for 15 minutes then cycled at 95°C - 15 seconds, 60°C - 35 seconds, 72°C - 35 seconds for 40 cycles. PCR reactions were pooled, each pool contained either 10 or 100 PCR reactions. Uracil DNA glycosylase (Perkin Elmer) was added at a ratio of 1U per 10 PCR reactions. Completeness of 5 digestion was confirmed by agarose gel electrophoresis.

EXAMPLE 5

PURIFICATION OF DIGESTED PCR PRODUCTS

Each DNA glycosylase reaction was loaded onto a C8 aquapore RP300 column equilibrated with 0.1M TEAA, the column washed with 0.1M TEAA at a flow rate of 0.5 ml/min and elute with 0.1M TEAA in 60% v/v CH₃CN. Peaks were collected. Column eluates were desiccated on a Savant Speedivac, evaporative centrifuge, resuspended in water to the original volume and redessicated. Pellets were resuspended in 5 ml H₂O. Mass spectrometric samples were prepared as described in Example 6.

EXAMPLE 6 MASS ANALYSIS

- 3-Hydroxypicolinic acid is prepared at a concentration of 75mg/ml in 1:1 acetonitrile and water and stored at room temperature in a closed vial in the dark. A new matrix solution is prepared weekly. Cation exchange beads (Bio-Rad, 50W-X4, mesh size 100-200μm) in ammonium form were used to reduce interference from sodium and potassium adducts (Nordhoff et al, 1992). Samples were prepared as follows: 0.5μl matrix, 0.5μl sample (10pmol DNA) and 0.5μl cation exchange resin were mixed on the slide and allowed to dry. The beads were then blown off with nitrogen gas. Samples were then analysed immediately.
- Samples were run on the Kratos Kompact MALDI 4 with 337nm laser or a Perspective Voyager MALDITOF machine. Linear negative mode was used for all spectra. Fifty shots were fired at 30 power setting 70 to find a sweet spot and then a further 50 shots were fired at the sweet spot to obtain the spectrum.

25

EXAMPLE 7 SIMULATION

In order to assess the ability of this technique to detect mutations, a computer simulation was designed. Two different stimulations were conducted, one that models a mutation occurring in a haploid genome and the other modelling a mutation occurring in a diploid genome on the background of a wildtype sequence.

In order to optimise the detection of mutations, four separate base specific cleavage reactions

10 have been performed using separated forward and reverse strands and two different base specific reagents, in this case, thymidine and cytosine. A random library of exonic sequences has been extracted from Genbank. This comprises 100,000 kb of coding sequence concatenated into one file. Sequence strings of incremental length are removed from this file. A fingerprint for each strand is generated. This is calculated by generating the sets of post cleavage fragments for each base-specific reagent and sorting the non-redundant fragments. Mutant sequences are created by mutating every residue in the wild-type sequence to each of three possible alternatives. The fingerprint of each mutant is generated and compared to the wild-type fingerprints. If the fingerprints are different, it is recorded as a successful detection and the next mutant examined. If the first base specific cleavage reaction is unable to detect the mutation on the forward strand, the reverse strand is tried and so on until the reverse strand of the second reagent fails. This represents the total failure rate under the described conditions. Conceivably one could increase the power of the technique by using all four base specific reagents on both strands.

EXAMPLE 8 DETECTION OF BASE MUTATIONS

Overlaid tracings from the mass spectrogram are presented in Figure 1. These show the cleavage products of two oligonucleotides 1 and 2 [SEQ ID NO:1 and SEQ ID NO:2, respectively], which differ at two nucleotides, one producing a fragment with a different nucleotide composition and the other introducing a new cleavage site. The new fragments resulting from these differences are easily separated. This example, observed masses deviate from calculated

by ±0.02-1%. This is sufficient to assign the correct base composition in this case, however, it is not sufficient to blindly assign base composition peaks from a sample of unknown sequence. A study has been done which concluded that all base compositions can be uniquely specified up to the 14mer level if one base has a known composition (ie. G=1 in the case of the study, or in our case, T=0) with a measurement of mass to within ±0.01%. This is presently achievable, dependent on the mass analyser used and the sample quality and quantity (Pomerantz et al, 1993).

Base specific cleavage and mass spectrometry is, therefore, able to differentiate between two identical length oligonucleotides with different nucleotide compositions and hence is able to differentiate between two sequences differing at one base (Table 1). Where a mutation changes the residue involved directly in the base specific cleavage reaction (a "U" residue in the case presented here), the difference in size of the resultant products is marked (Table 1). The accuracy of mass determination allows deduction of the base composition of each fragment and therefore, where the sequence is known, will enable deduction of the nature of the mutation.

Table 2 presents stimulation date for the haploid genome case and Table 3 presents the stimulation data where a mutation occurs in a diploid organism in the presence of a wild-type copy. These data are presented as cumulative "failure to identify" mutations based on both strands and two base specific cleavage reactions. Therefore, the last column, which is where the "C" reaction was unable to pick the mutation on the complementary strand represents the "total failure rate" of the technique under these conditions.

EXAMPLE 9

25 **DETECTION OF POINT MUTATIONS**

The method of the present invention has been employed on PCR products and is able to detect point mutations and an insertion in DNA that has been amplified using the polymerase chain reaction as discussed below. The PCR templates used, TUB and TUB-M are described in Example 1 and have three differences, two of which are point mutations and the third is an insertion/deletion. All of these differences are visible in the mass spectrograms (Figures 2 and

3). Figure 3 represents the reacted, separated products of both TUB-M and TUB. This is a reconstruction of a heterozygote. Figure 2 is reacted, separated products of TUB, representing, in this case a homozygote normal. Table 4 gives the expected masses for each fragment and the corresponding comments on whether they have been seen. All mutations were seen on either 5 both strands or on one strand only.

- 22 -

TABLE 1

oligo1:cl	eavage products	calc. mass	obs.mass
a	CCTCAT ¹	1810.2	1811.1
b	TTTT	1318.8	1318.4
c	TTGTAAGAGG ²	3190.0	3190.9
oligo2:cle	eavage products		
a	CCTCGT ³	1826.2	1828.2
b	TTTT	1318.8	1318.4
c	TTGT	1343.8	1343.5
d	AGAGG⁴	1635.0	1636.3

SEQ ID NO:18

SEQ ID NO:19

³ SEQ ID NO:20

SEQ ID NO:21

:	;	27	:
	5	=	-
;			
:	2	1	
	=	% N. M W.M. amp	
:			:
*****	:	II.H. Gyor.	
	2	į	
:			
2	:		
	13 57	31	
	:	3	
	:	2:	į
		Ĕ,	
•	=		7
		11 H 11 H 11 H	7

% "C" reverse failures	000	0000	0.01 0.01 0.01	0.02 0.03 0.02 0.03	0.05 0.05 0.08 0.08
Number of "C" reverse failures	-	7 - = -	32.22	288 203 203	147 155 188 236 3708
% "C" forward failures	0000	0.02 0.03 0.05	0.09	0.18 0.21 0.25	0.36 0.41 0.50 3.42
Number of "C" forward failures	1 14 26 43	72 93 145	188 264 348 500	541 643 759	1082 1221 1400 1507 10255
% "T" reverse failures	0.03 0.08 0.13	0.31 0.41 0.49	0.65 0.79 0.94		2.21 2.21 2.64 9.24
Number of "T" reverse failures	97 237 401 653	931 1225 1480	1955 2356 2828 3449	3923 4386 4904 5700	6130 6621 7445 7906 27716
% "T" forward failures	3.52 4.91 6.30 7.61	8.80 9.92 10.88	11.91 12.95 13.67	15.49 16.15 16.95 17.58	18.26 19.01 19.76 20.30 32.97
Number of "T" forward failures	10569 14723 18908 22825	26383 29751 32644	35692 38848 40970 43995	46387 48443 50812 52651	54768 56876 59231 60891 98902
Total number mutated sequences	300000 299880 300000 300000	299880 299880 300000	299700 300000 299640 299520	299520 299880 299700 299520	299880 299160 299820 300000
Total number wildtype sequences	2500 1666 1250 1000	833 714 625	555 500 454 416	384 337 312	274 277 100 100
Sequence length					340 380 1000 1000

Fable 2

:	:	-	
:	;		
-	=		
:	:	5	=======================================
*****	:	***************************************	-
	:	Ē	
***	:	******	
:	ä		
	::	:	
	,	:	
	:	;	
	25	:	
	-	11 11 11 11 11	

	•	- (7 (7	t u	7	۰ ٥	0 0	7) (4 6	7	t v	א כ	1 0	۰ ۵	0 0	۸ (- د	- 0	4 0	ሳ <	+ 4	5 4	1 0	77
% "C" reverse failures																										
Number of "C" reverse failures	3993	6426	0096	12556	16347	20145	23767	27141	30973	34684	38330	41402	45504	48553	51963	54874	58213	60609	64056	67463	69713	71853	74722	77298	79507	81602
% "C" forward failures	4	· * 2	7	. 0	=	13	15	16	8	61	21	22	23	25	26	27	28	29	30	32	32	33	34	35	36	37
Number of "C" forward failures	11468	16455	22043	27368	32832	38470	43686	48016	53122	57622	62015	65898	70162	73900	77929	81308	84764	87956	91319	94747	96836	99414	102503	104741	107376	109511
% "T" % reverse failures	13	9	19	22	24	27	29	31	33	35	36	38	39	\$	4	43	4	45	46	47	48	49	4	20	51	21
Number of "T" reverse failures	39139	48716	57790	65780	73381	81099	87388	92501	98957	103638	107959	112626	117075	120601	124257	127979	131116	134422	137686	140874	143182	145413	147958	149928	152227	153784
% "T" % forward failures	40	4	48	20	52	55	57	58	29	61	62	63	2	65	99	8	<i>L</i> 9	68	9	9	2	20	71	71	72	72
Number of "T" forward failures	120699	132516	142523	150441	156926	163973	169582	173319	178247	181728	184465	188025	191722	194210	196727	199290	200599	203752	205749	207767	209037	210530	212472	214285	215159	215902
Total num,ber mutated sequences	300000	299880	300000	30000	299880	299880	300000	299700	30000	299640	299520	299520	299880	299700	299520	299880	299160	299820	30000	299880	299640	299460	299520	300000	299520	299700
Total number wildtype sequences	2500	1666	1250	<u>00</u>	833	714	625	555	2 00	454	416	384	357	333	312	294	277	263	250	238	227	217	208	200	192	185
Sequence Length	40	8	80	<u>8</u>	120	140	160	180	200	220	240	260	280	300	320	340	360	380	4 00	420	4	460	480	200	520	540

Sable,

TABLE 4

EXPECTED TUB FRAGMENTS		FRAGMENTS NOT SEEN
GGC	1045.6	
CCAC	1198.8	
CCACA [SEQ ID NO:22]	1512*	
CCAG	1318.8	
GGAC	1358.8	
CCAGCCG [SEQ ID NO:23]	2226.4	
GCGCAAG [SEQ ID NO:24]	2210.4	
GCGCAAGA [SEQ ID NO:25]	2523.6*	
CCGCGAAC [SEQ ID NO:26]	2539.6	
GGAGCACGCAGG [SEQ ID NO:7]	3880.4	
CGGCAAGCACCGACAGG [SEQ ID NO:8]	5374.4	
GGTGACCTGAACCACCTCGTGCG [SEQ ID NO:9]	5888.8	PRIMER
CAGGCGCTTGAGACTGGACGCGT [SEQ ID NO:10]	6258	PRIMER
EXPECTED TUB-M FRAGMENTS		
CCAC	1198.8	END
CGAG	1358.8	
GGAC	1358.8	
CGAGGC [SEQ ID NO:27]	1977.2	
CCAGCCG [SEQ ID NO:28]	2226.4	
GCGCAAG [SEQ ID NO:29]	2210.4	
CGACAGCC [SEQ ID NO:30]	2539.6	
CCGCGAAC [SEQ ID NO:31]	2539.6	
CGAACGC [SEQ ID NO:32]	2579.6	
GGAGCACGCAGG [SEQ ID NO:11]	3880.4	
GGTGACCTGAACCACCTCGTGCG [SEQ ID NO:12]	5888.8	PRIMER
CAGGCGCTTGAGACTGGACGCGT [SEQ ID NO:13]	6258	PRIMER

* Fragments obtained due to the terminal transferase activity of Taq polymerase which results in the addition of a dATP at the 3' end of the PCR product.

EXAMPLE 10 MODIFICATION DETECTION PROTOCOL

The method of Example 8 is employed except DNA polymerase enzymes are employed with the ability to incorporate both dNTPs and rNTPs. Specific cleavage reactions are performed on PCR products in which one of the nucleotides is substituted for rNTP. This permits the base specific cleavage reactions to be conducted in alkali at high temperature.

EXAMPLE 11 IDENTIFICATION OF MUTATION POSITION

The method of Example 8 employs Uracil-N-glycososylase which cleaves DNA at uracil. It is, therefore, a T reaction as uracil is replacing thymidine in the PCR product. In this Example, cleavage occurs at each of other bases so as to create sets of overlapping data to give information about the position of the mutation.

EXAMPLE 12 DETERMINATION OF NUCLEOTIDE SEQUENCE

The method of the present invention is used to determine a nucleotide sequence of a nucleic acid fragment. The method employed is substantially as described in Example 8.

EXAMPLE 13 DETECTION OF PREVIOUSLY UNKNOWN MUTATIONS

The method of the present invention is further demonstrated on a sequence polymorphism in the IL-12 gene. This previously unreported sequence change results in a TaqI RFLP and, therefore, can be followed by enzymatic digestion of PCR products.

Methods

Template DNA was genomic DNA from human volunteers of each possible genotype of the IL-12 polymorphism (ie. +/+, +/-, and -/-, where + is the presence of the Taq restriction site). PCRs were carried out in 20µl reactions in 192 well plates in a Corbett Thermocycler with the following reaction mixture: 50mM KCl, 10mM Tris-HCl pH 8.3, 25mM MgCl, 2.5mM dATP, dCTP and dGTP (Promega), 5mM dUTP (Boehringer Mannheim GmbH), 0.5U AmpliTaq Gold (Perkin Elmer), 0.4µM primers (Bresatec). After an initial 15min incubation at 95°C, the reactions were cycled 95°C 15 secs, 58°C 35sec, 72°C 35sec, for 40 cycles. 7 reactions were pooled for the homozygotes and 9 for the heterozygote. 1 unit of AmpErase Uracil-Nglycosylase (Perkin Elmer) was added to each pool and the reaction incubated at 50°C for 1 hour, followed by 30 minutes at 105°C. The extend of completion of the cleavage reaction was monitored by the absence of a band on an agarose gel. The cleavage reaction was monitored by the absence of a band on an agarose gel. The cleavage products were purified using reverse phase HPLC on a 100x2.1mm C8 aquapore RP300 column (Applied Biosystems). The flow rate was 0.5ml/min and absorbance was monitored at 254nm. The sample washed with 0.1M triethylaminoacetate (TEAA) and eluted in 0.1M TEAA/60% w/v acetonitrile and the fraction with absorbance at 254nm was collected and evaporated to dryness using a Savant Speedivac. The residue was resuspended in 100µl distilled deionised water and evaporated to dryness and then resuspended in 1µl water. 0.5µl of this was mixed with 0.5µl 3-hydroxypicolinic acid (saturated solution in 50% w/v acetonitrile and 0.5µl NH₄⁺ ion-exchange beads (BioRad, 50W-X4, mesh size 100-200μm) on a sample slide. The mass spectrometer used to characterise the reaction products was a Voyager BioSpectrometry Workstation from PerSeptive Biosystems. 128 laser pulses at power 1800 were averaged. Post Source Decay spectra were collected using a Kratos Kompact MALDI4 TOF mass spectrometer with 377nm laser and a curved field reflector in positive ion mode. Matrix and sample preparation as above. After scanning in linear mode for the sweet spot, the ion gate was set 34.8 Da above and 36.2 Da below the parent ion at 1727.2 Da. 200 profiles at 5 shots per profile were averaged. Spectra were corrected for the curved field.

Genotypes were confirmed by demonstrating the presence or absence of the TaqI restriction site

WO 98/54571 PCT/AU98/00396

- 28 -

by digesting PCR products with TaqI restriction enzyme (Gibco-BRL) and analysing the products by agarose electrophoresis. DNA bands were stained with ethidium bromide.

A computer simulation of the method has been written and 100kb of random coding sequence from Genbank has been fed into it. The program takes discrete-length bites of sequence from a file of concatenated cDNA sequence from Genbank. Each base is mutated to each hypothetical variant of the original sequence by removing the cleaved base leaving the residual short strings. The mass spectrometry was modelled, fragments of different nucleotide composition being distinguishable and those of identical composition being indistinguishable. As quantitation is difficult on the MALDI, changes in peak height was not used as an indication of a change in underlying sequence. The program then compares "spectra" and tallies the number of mutations that were missed. The program can model the detection of a mutation in the presence of a wildtype sequence (heterozygote) or can model the differences between two homozygotes. In the first case a mutation can only be detected by the presence of a new peak and in the latter case, as well as the presence of a new peak, the disappearance of a peak can also signal a change. All four base specific cleavage reactions were used and reactions were performed on separated strands giving a total of 8 reactions per PCR product. Also the model has been refined to take account of the ability of post source decay (PSD) to identify changes in peaks containing a complex mix of oligonucleotides. In this case fragments of different sequence are distinguishable.

Results

A PCR assay was designed to incorporate the mutated region and then subjected to uracil -N glycosylase treatment. The products were purified and analysed by MALDI-TOF mass spectrometry. The sequence of the PCR primers and product along with the mutation are shown in Figure 4. The C to T change gives rise to a Taq RFLP and this can be seen in homozygote and heterozygote state in Figure 5. The spectra generated by the MALDI-TOF can also be seen in Figure 5. The expected and observed masses of the cleavage products from the two alleles are given in Table 5. The position of the mutation and deduction of the changed base is evident from study of this Table.

A limitation to the sensitivity of this method results from the lack of quantitative data available from the MALDI. When the fragment derived from the mutated sequence coincides with other fragments of identical nucleotide composition in the wild-type sequence, its disappearance will go undetected. Similarly, the appearance of a new fragment in the mutated sequence will go unnoticed of it has identical nucleotide composition to one or more other cleavage products. If both these conditions exist for all cleavage reactions, then the mutation will be missed. This technique, therefore, is not as advantageous for longer fragment as for small fragments.

To address this problem, the inventors employed a second dimension detection protocol on the MALDI-TOF machine. Post source decay (PSD) uses the dissociation of the highly energised ions during their flight to the detector as this second dimension. They are directed into an electric field of opposite polarity and are reflected. The smaller ions are reflected earlier and reach the detector first. As the spectrum from the decay is dependent on the sequence of the oligonucleotide (and not the nucleotide composition), the aforementioned limitation is bypassed, generating a method of mutation detection that is now extremely sensitive.

The utility of MALDI-TOF analysis with PSD is demonstrated in Figure 6 where two oligonucleotides of identical nucleotide composition are separated by MALDI-TOF using PSD. The resulting spectra are quite distinguishable. Sequence determination of small oligonucleotides is feasible using molecular dissociation methods and, therefore, the subject method extrapolates into an accurate resequencing protocol.

A computer simulation of data from the linear separation of cleavage products has been written. Using Genbank data, the expected number of base substitution that would be identified when comparing two homozygotes over a 250bp PCR distance is 98.5%. the comparable figure is 95% when a homozygote is compared to a heterozygote. If each mass peak from a base specific cleavage is analysed using a secondary dissociation technique, eg. PSD on the MALDI-TOF machine, then sensitivity of mutation detection improves dramatically. This has also been simulated and for a 1000bp fragment subjected to base specific cleavage, and analysed with PSD, 99% of all substitutions will be detected for a homozygote to heterozygote comparison and 99.8% when two homozygotes are compared.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

- 31 -

BIBLIOGRAPHY

- Cotton, R.G., Rodrigues, N.R., and Campbell, R.D. (1988). Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations. *Proceedings of the National Academy of* Sciences of the United States of America 85: 4397-401.
- 2. Hattori, M., Shibata, A., Yoshioka, K., and Sakaki, Y. (1993). Orphan peak analysis: a novel method for detection of point mutations using an automated fluorescence DNA sequencer. *Genomics* 15: 415-417.
- Lipshultz, R.J., Morris, D., Chee, M., Hubbell, E., Kozal, M.J., Shah, N., Shen, N., Yang, R., and Fodor, S.P. (1995). Using oligonucleotide probe arrays to access genetic diversity. *Biotech.* 19: 442-447.
- Lui, Y-H., Bai, J., Zhu, X., Liang, X., Siemieniak, D., Venta, P.J., and Lubman, D.M. (1995). Rapid screening of genetic polymorphisms using buccal cell DNA with detection by Matrix Assisted Laser Desoprtion/Ionization Mass Spectrometry. Rapid Commun. Mass Spectrom. 9: 735-743.
- Nordhoff, E., Ingendoh, A., Cramer, R., Overberg, A., Stahl, B., Karas, M., Hillenkamp, F., and Crain, P.F. (1992). Matrix-assisted laser desorption/ionization mass spectrometry of nucleic acids with wavelengths in the ultraviolet and infrared. *Rapid Commun. Mass* Spectrom. 6: 771-776.
- 6. Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K., and Sekiya, T. (1989). Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. *Proceedings of the National Academy of Sciences of the United States of America* 86: 2766-70.
- 7. Pomerantz, S.C., Kowalak, J.A. and McCloskey, J.A. (1993). Determination of oligonucleotide composition from mass spectrometrically measured molecular weight. J. Am. Soc. Mass Spectrom. 4: 204-209.

- 32 -

SEQUENCE LISTING

- (1) GENERAL INFORMATION:
 - (i) APPLICANT: (Other than US): THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

(US only): FOOTE Simon, ELSO Colleen, SIMPSON Richard, REID

Gavin

- (ii) TITLE OF INVENTION: A NOVEL METHOD
- (iii) NUMBER OF SEQUENCES: 32
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: DAVIES COLLISON CAVE
 - (B) STREET: 1 LITTLE COLLINS STREET
 - (C) CITY: MELBOURNE
 - (D) STATE: VICTORIA
 - (E) COUNTRY: AUSTRALIA
 - (F) ZIP: 3000
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: PCT INTERNATIONAL
 - (B) FILING DATE: 28 MAY 1998
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA
 - (A) APPLICATION NUMBER: PO 7102
 - (B) FILING DATE: 28 MAY 1997
 - (A) APPLICATION NUMBER: PO 7109
 - (B) FILING DATE: 30 MAY 1997
 - (A) APPLICATION NUMBER: PP 1665
 - (B) FILING DATE: 5 FEBRUARY 1998
 - (A) APPLICATION NUMBER: PP3592
 - (B) FILING DATE: 19-MAY-1998
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: HUGHES, DR E JOHN L
 - (C) REFERENCE/DOCKET NUMBER: EJH/AF
- (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: +61 3 9254 2777 (B) TELEFAX: +61 3 9254 2770

(C) TELEX: AA 31787

50

70

(2) INFORMATION FOR SEQ ID NO:1:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(ii) MOLECULE TYPE: DNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:	
CCTCATUTTT TUTTGTAAGA GG	22
(2) INFORMATION FOR SEQ ID NO:2:	
(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:	
CCTCGTUTTT TUTTGTUAGA GG	22
(2) INFORMATION FOR SEQ ID NO:3:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 70 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(ii) MOLECULE TYPE: DNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:	

GGTGACCTGA ACCACCTCGT GCGTCCAGCC GTTCGTGGCT GTCCAGTCCG

CAAACTCTGA CCTGCGCAAG

(2) INFORMATION FOR SEQ ID NO:4:

- 35 -

(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 69 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: single	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:	
GGTGACCTGA ACCACCTCGTG CGTCCAGCCG TTCGAGGCTG TCGAGTCCGC	50
(G) AACTCTGAC CTGCGCAAG	6-9
(2) INFORMATION FOR SEQ ID NO:5:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 20 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: single	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:	
GGTGACCTGA ACCACCTCGT	20
(2) INFORMATION FOR SEQ ID NO:6:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 18 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: single	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:	
CTTGCGCAGG TCAGAGTT	18

- 36 -

(2)	INFORMATION FOR SEQ ID NO:7:	
	 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCL DESCRIPTION: SEQ ID NO:7:	
GGA	GCACGCAG G	11
(2)	INFORMATION FOR SEQ ID NO:8:	
	 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:	
CGG	CAAGCAC CGACAGG	17
(2)	INFORMATION FOR SEQ ID NO:9:	
	(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:	
GGT	PGACCTGA ACCACCTCGT GCG	23
(2)	INFORMATION FOR SEQ ID NO:10:	

(i) SEQUENCE CHARACTERISTICS:

- 37 -

	(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid	
	(C) STRANDEDNESS: single	
	(D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:	
CAGG	CGCTTG AGACTGGACG CGT	23
(2)	INFORMATION FOR SEQ ID NO:11:	
	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 12 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: single	
	(D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:	
GGAG	CACGCA GG	12
(2)	INFORMATION FOR SEQ ID NO:12:	
	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 23 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: single	
	(D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:	
GGTC	GACCTGA ACCACCTCGT GCG	23
(2)	INFORMATION FOR SEQ ID NO:13:	
	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 23 base pairs	
	(B) TYPE: nucleic acid	

(C) STRANDEDNESS: single

- 38 -

(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:	
CAGGCGCTTG AGACTGGACG CGT	23
(2) INFORMATION FOR SEQ ID NO:14:	
(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 124 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:	
CACAACGGAA TAGACCCAAA AAGAUAAUUU CUAUCUGAUU UGCUUUAAAA CGUUUUUUUUA GGAUCACAAU GAUAUCUUUG CUGUAUUUGU AUAGUUCGAU GCUAAAUGCU CAUUGAAACA AUCA	50 50 24
(2) INFORMATION FOR SEQ ID NO:15:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 124 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(ii) MOLECULE TYPE: DNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:	
GUGUUGCCUU AUCUGGGUUU UUCUAUUAAA GAUAGACUAA ACGAAAUUUU GCAAAAAAAU CCUAGUGUUA CUAUAGAAAC GACAUAAACA UAUCAAGCUA CGATTTACGA GTAACTTTGT TAGT	50 50 24
(2) INFORMATION FOR SEQ ID NO:16:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 base pairs	

(B) TYPE: nucleic acid

6

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CATCCT 6

- (2) INFORMATION FOR SEQ ID NO:17:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CACCTT 6

- (2) INFORMATION FOR SEQ ID NO:18:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CCTCAT

- (2) INFORMATION FOR SEQ ID NO:19:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 40 -

í	' i i	١	MOLECULE	TVDF.	בזאכו
ı		. ?	MOLECULE	LIFE	DIVA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TTGTAAGAGG 10

- (2) INFORMATION FOR SEQ ID NO:20:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CCTCGT 6

- (2) INFORMATION FOR SEQ ID NO:21:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AGAGG 5

- (2) INFORMATION FOR SEQ ID NO:22:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA

- 41 -

	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:	2:
CCA	CACA	5
(2)) INFORMATION FOR SEQ ID NO:23:	
	(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 7 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23	:
CCAC	AGCCG	7
(2)) INFORMATION FOR SEQ ID NO:24:	
	(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 7 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24	:
GCG	GCAAG	7
(2)) INFORMATION FOR SEQ ID NO: 25:	
	(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 8 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear	
	(ii) MOLECULE TYPE: DNA	

GCGCAAGA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

6

- (2) INFORMATION FOR SEQ ID NO: 26:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: CCGCGAAC

CGAAC 8

- (2) INFORMATION FOR SEQ ID NO:27:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

CGAGGC

- (2) INFORMATION FOR SEQ ID NO: 28:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

CCAGCCG 7

- (2) INFORMATION FOR SEQ ID NO: 29:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 base pairs

GCGCAAG

CGACAGCC

CCGCGAAC

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear

(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29: (2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: (2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: (2) INFORMATION FOR SEQ ID NO: 32:

7

8

8

- 44 -

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

CGAACGGC 8

CLAIMS:

- 1. A method of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising subjecting the test nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.
- 2. A method according to claim 1 wherein the nucleic acid molecule to be tested is amplified by a polymerase chain reaction (PCR) prior to base specific cleavage.
- 3. A method according to claim 1 or 2 wherein the base specific cleavage results in oligonucleotide fragments of from about 2 bases to about 1000 bases.
- 4. A method according to claim 3 wherein the base specific cleavage results in oligonucleotide fragments of from about 3 bases to about 500 bases.
- 5. A method according to claim 4 wherein the base specific cleavage results in oligonucleotide fragments of from about 4 bases to about 100 bases.
- 6. A method according to any one of claims 1 to 5 wherein the base specific cleavage is uracil specific cleavage.
- 7. A method according to claim 6 wherein the uracil specific cleavage is mediated by uracil-N-glycosylase.
- 8. A method according to any one of claims 1 to 7 further comprising subjecting

WO 98/54571 PCT/AU98/00396

- 46 -

fragmentation products to further separation (PSD) to generate a spectrum from decay dependent on the nucleotide sequence of the oligonucleotide.

- 9. A method according to claim 8 wherein the further separation of fragmentation products is by post source decay (PSD).
- 10. A computer programme capable of controlling a method of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising subjecting the test nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.
- 11. A method according to claim 9 wherein the nucleic acid to be tested is amplified by PCR prior to base specific cleavage.
- 12. A method according to claim 9 or 10 wherein the base specific cleavage results in oligonucleotide fragments of from about 2 bases to about 1000 bases.
- 13. A method according to claim 9 wherein the base specific cleavage results in oligonucleotide fragments of from about 3 bases to about 500 bases.
- 14. A method according to claim 10 wherein the base specific cleavage results in oligonucleotide fragments of from about 4 bases to about 100 bases.
- 15. A method according to any one of claims 9 to 13 wherein the base specific cleavage is uracil specific cleavage.

- 16. A method according to claim 14 wherein the uracil specific cleavage is mediated by uracil-N-glycosylase.
- 17. A method according to any one of claims 10 to 16 further comprising the further separation of fragmentation products to generate a spectrum from decay dependent on the nucleotide sequence of the oligonucleotide.
- 18. A method according to claim 17 wherein the further separation of fragmentation products is by post source decay (PSD).
- 19. An apparatus capable of detecting a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said apparatus comprising means of subjecting the test nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.
- 20. An apparatus according to claim 19 further comprising further fragmentation separation means to generate a spectrum from decay dependent on the nucleotide sequence of the oligonucleotide.
- 21. An apparatus according to claim 20 wherein the further fragmentation separation means is post source decay (PSD).
- 22. Use of MALDI-TOF in the detection of a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule.
- 23. Use according to claim 22 further comprising use of PSD to generate a spectrum for

decay dependent on the sequence of an oligonucleotide.


- 24. A method for identifying and/or locating a mutation in one or more bases in a target nucleic acid molecule, subjecting the test nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-TOF MS and/or other equivalent procedure to produce a fingerprint of the oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.
- 25. A method according to claim 24 wherein the nucleic acid molecule to be tested is amplified by a polymerase chain reaction (PCR) prior to base specific cleavage.
- 26. A method according to claim 24 or 25 wherein the base specific cleavage results in oligonucleotide fragments of from about 2 bases to about 1000 bases.
- 27. A method according to claim 26 wherein the base specific cleavage results in oligonucleotide fragments of from about 3 bases to about 500 bases.
- 28. A method according to claim 27 wherein the base specific cleavage results in oligonucleotide fragments of from about 4 bases to about 100 bases.
- 29. A method according to any one of claims 24 to 28 wherein the base specific cleavage is uracil specific cleavage.
- 30. A method according to claim 29 wherein the uracil specific cleavage is mediated by uracil-N-glycosylase.
- 31. A method according to any one of claims 24 to 30 further comprising subjecting fragmentation products to further separation (PSD) to generate a spectrum from decay

dependent on the nucleotide sequence of the oligonucleotide.


32. A method according to claim 31 wherein the further separation of fragmentation products is by post source decay (PSD).

ABSTRACT

A method of detecting a mutation or a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising subjecting the test nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-ATOF MS and/or other equivalent procedure to produce a fingerprint of then oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.




2/13



-16 2

PCT/AU98/00396



UCU AGA CAA GUU AGU UGC ACG AAA UUU CGA GCU GGA UAA AAU AGA GNN CAA UUU AUA UAU UUU AAA Gun UGU ACA CAA GGU AUU AAC GAC CUG UAA UAU UAA ngn ATA ACA ACG AAC GGA CCU CNN CUU UGC GAA UUG GAU UUG AAC GAA UAU CUA

CUC AUU <u>GAA ACA A</u>UC A GAG TAA CTT TGT TAG T


F16 4


A


5/13


Figure 5A


+/- -/- +/+ +/- +/-(bp)
124
97
























COMBINED DECLARATION FOR PATENT APPLICATION AND FORCE OF ATTORNEY

I believe I am the or	izina i ra ind sole inventor i	is any one name is asted below) or an original, test and ioni-
transfer on the control	. al	neer miner which is climed and for which a patent is some in
		mass spectrometry or mass separation and
<u>base</u> specific	cleavage"	
the specification of wh	ich icheck only one item below	ı
🔲 is its icher! he	70f0	
wishled is t	nited States application	
Serial No		. <u></u>
M)		
oid was ameni	ded	
on	-	or applicable)
⋈ was filed as PC	Lorternational application	
Number	PCT/AU98/00396	-
M	28 May 1998	

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above

_____ (if applicable)

I acknowlege the dury to disclose information which is material to the examination of this application in accordance with full 37. Code of Federal Regulations, §1.56(a)

I hereby claim foreign priority benefits under Title 35. United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or inv PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

<u> </u>	7 15 55, NO	16.77 B. C. Mily 1.00 - 11.75 - 11.75	
Australia	PO 7102	28 May 1997	≫ =
Australia	PO 7109	30 May 1997	X
Australia	. PP 1665	5 February 1998	17 0 es
Australia	PP 3592	19 May 1998	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
mustru ru			U

Combined Declaration		Han bir ing series of the seri	. /	/O,
	,			MAR
क्षेत्र काल्याच्या । स्थापना मुख्या	by springliporautaph on Adelmed in Edie sign material maximum	of Fig. 1. United States Code (Co. 3) and Code (Code (Social which occurred hower date of this application	E R
PRIOR U.S. APPL 35 U.S.C. 120	ICATIONS OF PCT INTER	RNATIONAL APPLICATIONS DESIGNATE	ING THE U.S. FOR RENEFIT UN	DFR.
37030 127	* 7500 41V 14	14.7	2 CA 10 X 3	
	, yes			
				_ ·
,	THE CALL MANCE HAND			··
N .	1 2000	<u> </u>		
T/AU98/00396	28 May 1998			
euneth L. King, Rej nhn S. Sonany, Reg onald T. Ulack, Reg nd Correspondence to	No. 28 757; Mark J No. 27,999.	business in the Patent and Trade opoid Presser, Reg. No. 19,877; K.S. DiGiglio, Reg. No. 31,348, Par. Cohen, Rog. No. 32,211; Richar	Direct telephone Calls to the commercial telephone	
enneth L. King, Rej ohn S. Sonany, Reg onald T. Ulack, Reg and Correspondence to	No. 28, 757; Mark J	. Cohen, Rog. No. 32,211; Richar	Direct Leiephone Calls In	
enneth L. King, Regon S. Sonany, Regonald T. Ulack, Regond Correspondence to	. No. 28 757; Mark J r. No. 27 999. Scully, Scott, Mu 400 Gacden City P	Cohen, Reg. No. 32,211; Richar	Direct telephone Calls to the commercial telephone	
enneth L. King, Rej hhn S. Sonsany, Reg onald T. Ulack, Reg nd Correspondence to FOOTE	. No. 28 757; Mark J r. No. 27 999. Scully, Scott, Mu 400 Gacden City P	. Cohen. Reg. No. 32,211; Richar Irphy & Presser Plaza 11530	Direct Lelephone Calls in manic and length on employed Calls in Leopold Prender (516) 742-4343	
euneth L. King, Rej hhn S. Sonany, Reg onald T. Ulack, Reg nd Correspondence to FOOTE Fairfie	No. 28, 757; Mark J r. No. 27, 999. Scully, Scott, Mu 100 Garden City P Garden City, NY	Cohen, Reg. No. 32,211; Richard Presser Plaza 11530 Simon Victoria, Australia	Direct telephone Calls to make and telephone combed Leopold Prenser (516) 742-4343	,508 an
eineth L. King, Rej hhn S. Sonany, Reg onald T. Black, Reg and Correspondence to FOOTE Fairfie 19 Park	No. 28, 757; Mark J r. No. 27, 999. Scully, Scott, Mu 100 Garden City P Garden City, NY	Cohen, Rog. No. 32,211; Richard Presser 1224	Direct Lelephone Calls to manic and length on employed Calls to the Copold Prender (516) 742-4343	,508 att
enneth L. King, Rej whn S. Sonsny, Reg onald T. Wlack, Reg and Correspondence to FOOTE Fairfie	No. 28, 757; Mark J r. No. 27, 999. Scully, Scott, Mu 100 Garden City P Garden City, NY	Cohen, Rog. No. 32,211; Richard Presser Plaza 11530 Simon Victoria, Australia Fairfield, Victoria. Colleen	Direct telephone Calls in memiciand lengthme authors Leopold Prenser (516) 742-4343 Australia 3078 Australia	,508 att
enneth L. King, Rejohn S. Sonany, Regonald T. Ulack, Regonald T. Ulack, Regonald Correspondence to FOOTE Fairfie 19 Park LAMP ELSO Northco	No. 28, 757; Mark J r. No. 27, 999. Scully, Scott, Mu 100 Garden City P Garden C) ty, NY Id Street	Cohen, Rog. No. 32,211; Richard Presser Plaza 11530 Simon Victoria, Australia Fairfield, Victoria.	Direct telephone Calls in memiciand lengthme authors Leopold Prenser (516) 742-4343 Australia 3078 Australia	,508 an
FOOTE The state of the state o	No. 28, 757; Mark Jr. No. 27, 999. Scully, Scott, Mu 100 Garden City P Garden City, NY Id All Street	Cohen, Rog. No. 32,211; Richard Roger Resser Presser Plaza 11530 Simon Victoria Australia Fairfield Victoria Collecn	Direct telephone Calls in themse and telephone multiples Leopold Prenser (516) 742-4343 Australia	3
FOOTE The state of the state o	No. 28, 757; Mark J No. 27, 999. Scully, Scott, Mu 100 Garden City P Garden City, NY Id Street te stmas Street	Cohen, Rog. No. 32,211; Richard Presser Plaza 11530 Simon Victoria, Australia Fairfield, Victoria, Colleen Victoria, Australia	Direct Lelephone Calls in the control of the contro	3
FOOTE FOOTE FOOTE FOOTE 19 Park ELSO Northco 26 Chri SIMPSON	No. 28, 757; Mark J No. 27, 999. Scully, Scott, Mu 100 Garden City P Garden City, NY Id A Street te A Street	Simon Victoria, Australia Fairfield, Victoria, Colleen Victoria, Australia Richard	Direct telephone Calls to memor and telephone combed to the complete combed to the complete combed to the complete compl	3
FOOTE Fairfie 19 Park ELSO Northco SIMPSON Richmon	No. 28, 757; Mark J No. 27, 999. Scully, Scott, Mu 100 Garden City P Garden City, NY Ld A Street te A Street d A A A A A A A A A A A A A A A A A A	Simon Victoria, Australia Fairfield, Victoria, Colleen Victoria, Australia Richard Victoria, Australia Northcote, Victoria Richard Victoria, Australia	Direct Leiphone Calls in the complete dual ference complete Calls in the complete complete Calls in the complete calls in the call in the ca	a
FOOTE Fairfie 19 Park 26 Chri SIMPSON Richmon 42 Stan	No. 28, 757; Mark J No. 27, 999. Scully, Scott, Mu 100 Garden City P Garden C) ty, NY Id Street te stmas Street	Cohen, Reg. No. 32,211; Richard Presser 1222 Richard Presser 1222	Direct telephone Calls to memeral telephone Calls to memeral telephone comber Leopold Prenser (516) 742-4343 Transport of the American Australia State of the American Australia State of the American Australia State of the American State of t	a a a a a a a a a a a a a a a a a a a
FOOTE Fairfie 19 Park 26 Chri SIMPSON Richmon 42 Stan	No. 28, 757; Mark J No. 27, 999. Scully, Scott, Mu 100 Garden City P Garden C) ty, NY Id Street te stmas Street	Cohen, Reg. No. 32,211; Richard Presser Plaza 11530 Victoria, Australia Fairfield, Victoria Colleen Victoria, Australia Northcote, Victoria Richard Victoria, Australia Richmond, Victoria, de teres a un more knowledge de transcription de transcription des statements de mortale de pomishable de une compose une that such winter l'actre e processor de per that such winter l'actre e per that such actre e p	Direct telephone Calls to memeral telephone Calls to memeral telephone comber Leopold Prenser (516) 742-4343 Transport of the American Australia State of the American Australia State of the American Australia State of the American State of t	a a a a a a a a a a a a a a a a a a a

[] Signature for fourth and subsequent joint inventors.

Number of pages added ______.

	Ω			
\\display	1	RE ID-	Gavin	
ار ایز	4.1, (15.1) (14.1) 195, 441	Essendon HUX	Victoria. Australia	Australia
,	MONT POLICE	330 Pascoe Vale Road	Essendon, Victoria	3040. Australia
	CORT MANAGE	TANK - WATE	PRICE CONTRACTOR	COUNTY OF CITIZENS
55	स्व देशाचा देशा है की उन्हें देशा देशा है		Zavil der toder dante.	COURSES AND CORP. COMPANY
	COST DEFEE	trestents (Algunes)	.15	
	THE TAME	CAMPA MAR	UNSTRUCTO NAME	STOCKNICH VENN
9 0	OF SHIP NO F A	,17 Y	Z ² (M ± 2) ope 2 s ope H ² US (C// DF SUS.	STATE & JIP CONF. LOUNTRY
•	MOST CIFFLE ADDRESS	pass, regerace actions as	CHA	STATE A VIET TO A NAME
	HINDENTIN	1 (AH) - 5 (AH	EBDCL 7 ICE SCOAMI	Section 2014 and
27.2	OF SIDEACE &	.1 .	Company of the Special Company	- STATES (APERICAN)
	1 (18) (20) (1 (1 (18) (20) (1 (18) (20) (1 (18) (20) (20) (20) (20) (20) (20) (20) (20	e eres audus	(1)	epications a MAM
	त्यम् गठभा व भित्रमाणः	. 150 - 110	Civil 10 CIVO	CERTAINS OF STREET
208	RETURNET N		NUMBER OF CHARLEST STORY	STATE STREETING COUNTY
	Principle of ACOMMS.	A STATE OF STATE OF	(1)	Change use Namal
	THE MARKET	1 856 AS	THE TANK THAM	1 JUNITAL IS CHIVENZUIP
203	RESIDENCE N CHIZENSLIN	(1)	TATELOG HANGERONIES	STATE & ZIP COUL "COUNTRY
	POST OFFICE ADDRESS	DURLINERS VINAMAR	istv	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and behief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon

the application of any burners	TO A COURT OF PRIVIPITOR 205	SUPATCHE OF INVENTOR 206
10AH	DATE	DATE
MATURIALINATION 207	- 1 - A LUTE IN INVENTOR 208	SIGNATURE OF INVENTOR 209
0	(0.51)	PAB